Apolipoprotein E4 Frequencies in a Japanese Population with Alzheimer's Disease and Dementia with Lewy Bodies

• Published in: PloS one Vol. 6; no. 4; p. e18569
• Main Authors: Kobayashi, Seiju, Tateno, Masaru, Park, Tae Woo, Utsumi, Kumiko, Sohma, Hitoshi, Ito, Yoichi M., Kokai, Yasuo, Saito, Toshikazu
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 28.04.2011; Public Library of Science (PLoS)
• Subjects: Advertising executives; Age; Aged; Alleles; Alzheimer Disease - diagnosis; Alzheimer Disease - genetics; Alzheimer's disease; Apolipoprotein E4; Apolipoprotein E4 - genetics; Apolipoproteins; Asian Continental Ancestry Group - genetics; Biomedical engineering; Case-Control Studies; Consortia; Dementia; Dementia disorders; Deoxyribonucleic acid; Diagnosis; Diagnostic systems; DNA; Drug dosages; Ethnicity; Female; Gene Frequency; Genetic aspects; Genotype; Genotype & phenotype; Genotypes; Health risks; Humans; Japan; Lewy bodies; Lewy Body Disease - diagnosis; Lewy Body Disease - genetics; Magnetic resonance imaging; Male; Medical research; Medicine; Middle Aged; Neurobiology; Neurodegenerative diseases; Risk factors; Scintigraphy; Single photon emission computed tomography; Studies; Japan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0018569

The apolipoprotein E (APOE) ε4 allele has been reported to be a risk factor for Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). Previous neuropathological studies have demonstrated similar frequencies of the APOE ε4 allele in AD and DLB. However, the few ante-mortem studies on APOE allele frequencies in DLB have shown lower frequencies than post-mortem studies. One reason for this may be inaccuracy of diagnosis. We examined APOE genotypes in subjects with AD, DLB, and a control group using the latest diagnostic criteria and MRI, SPECT, and MIBG myocardial scintigraphy. The subjects of this study consisted of 145 patients with probable AD, 50 subjects with probable DLB, and a control group. AD subjects were divided into two groups based on age of onset: early onset AD (EOAD) and late onset AD (LOAD). All subjects had characteristic features on MRI, SPECT, and/or myocardial scintigraphy. The rate of APOE4 carrier status was 18.3% and the frequency of the ε4 allele was 9.7% in controls. The rate of APOE4 carrier status and the frequency of the ε4 allele were 47% and 27% for LOAD, 50% and 31% for EOAD, and 42% and 31% for DLB, respectively. The APOE4 genotypes in this study are consistent with previous neuropathological studies suggesting accurate diagnosis of AD and DLB. APOE4 genotypes were similar in AD and DLB, giving further evidence that the ε4 allele is a risk factor for both disorders.